Table 2.

Comparison of Key Outcomes Pre- and Post-Methenamine Suppression

	Pre- methenamine	Post- methenamine	p-value
UTI rate, n/1000 follow-up days	9.16	5.01	0.0001
Length of antibiotic therapy to treat UTI, n/1000 follow-up days	152	88	0.0022
Length of antibiotic suppressive therapy, n/1000 follow-up days	13.7	0	<0.0001
Length of therapy for non-UTI antibiotics, n/1000 follow-up days	69	83	0.8655
TMP-SMX prophylaxis length of therapy, n/1000 follow-up days	849	895	0.7080
Hospitalizations due to UTI, n/1000 follow-up days	2.64	1.07	0.0456
Hospitalizations (other cause), n/1000 patient days	3.72	2.03	0.1244
Untreated ASB, n/1000 follow-up days	0.58	0.85	0.1344
Treated ASB, n/1000 follow-up days	0.66	0.85	0.2290
Culture negative treated UTI, n/1000 follow-up days	0.83	0.96	0.8062
Creatinine, median	1.24	1.21	0.8723
GFR ml/min/1.73m2, median	50.5	51.0	0.9942
Urinary pH, median	5.50	6.00	0.3203
MDR organisms isolated, % of positive bacteria cultures	0.08	0.07	0.6145